Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior - Wikidata - awgldk - TriplyDB

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

http://www.wikidata.org/entity/Q28191637

about

Pharmacotherapy of methamphetamine addiction: an update Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development Dopamine D4 receptors in psychostimulant addiction Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice An increase in tobacco craving is associated with enhanced medial prefrontal cortex network coupling Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.In vivo imaging of cerebral dopamine D3 receptors in alcoholism.Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors.D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response.Smoking cessation therapy with varenicline Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.Imaging of brain dopamine pathways: implications for understanding obesity.Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats Neuropharmacology and potential efficacy of new treatments for tobacco dependence.Dopamine D3 receptor ligands for the treatment of tobacco dependence.Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration.Mechanism-based medication development for the treatment of nicotine dependence.Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats.The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats.The selective D₃ receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preference The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice.Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity Effects of nicotine in experimental animals and humans: an update on addictive properties Genetic variation in the dopamine pathway and smoking cessation.Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists [Future medications for tobacco and cannabis dependence].Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration.Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.Dopamine D3 receptor antagonists: a patent review (2007 - 2012).Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.

P2860

Q24648913-F5A56211-8EF7-44FC-B7B7-2714B28E396A Q27014737-76880BA4-5ECF-4F3D-BE89-64835FCF58D8 Q27026759-35F729E0-F94C-440B-BA55-62B9F0493D88 Q27305163-33256745-4E7C-4E4D-BE88-CAB923ABA87C Q28256337-E48BD9D9-9F9A-4AEA-9EC0-D57B509A4176 Q28256384-96767BFF-1463-4769-9D28-0B5A39025738 Q28296440-5C8625CA-7506-4C48-8B08-1200504C4946 Q28539560-09D70695-AE56-4DA1-9BE5-AEBB3ACD7FCF Q30855960-43BF59D8-E492-473E-A989-E8C76D5DC20D Q33620597-AC02D9D6-8A96-495F-A9DA-52747A621061 Q34414507-8DC13CE7-B344-4DCC-8178-31483DC1E64E Q34671760-713A6B89-42D4-4701-9004-B46E11E5308E Q34805380-0253277F-7B49-4B62-AB72-0F5D99E48F7F Q34982537-F5878CDA-9510-43EF-99CE-347F06E53432 Q34995403-6E162D29-C42A-4081-ADC8-FA121E236490 Q35143623-EF1E6C48-5BFE-4079-B280-3681B82C2161 Q35679955-7EBE91B2-74FC-41DF-B90B-F097E6F2217B Q36042479-AA52CFE3-3C4E-42A3-B454-887820E411DB Q36174102-5AEB55B2-2B77-4CB8-A96E-4614859233D3 Q36376434-DE1DA0A2-A580-449E-9495-8F4D2695D910 Q36677397-7076E45F-3BB2-43CA-A56E-02BEBD241708 Q36850568-69D4DE71-20F9-4DCE-8CD4-180B882B0FFD Q37018610-6AA4A656-DA91-4BA0-B71F-5159721910AF Q37052512-341646E8-1F9E-4631-99C6-85DE7525BB82 Q37052544-116B00A2-8C9D-42DD-B480-DA0EE4148A5F Q37057993-DE3BCC56-A41C-43C0-82EA-9A9B77AADFCE Q37066079-3F194C5F-0FBF-46A5-8CA0-213494E5AB6C Q37162152-5F0C08EA-0D6B-4742-823B-7395F5B931E7 Q37164812-834DE302-BD93-49CF-BAFB-F0BACA8BF6EF Q37189418-3B50683C-F851-4405-BE08-02C80F88886B Q37203879-E762E0A4-B102-4A0B-A0C1-A635E89FF9A0 Q37264547-F5882BDD-9686-4A5F-9E54-7540B4283D3A Q37294037-47BC376D-6B21-4DC0-A38A-9EB3FBEAC06B Q37347842-456B1B89-A1BC-4421-B405-75E092F8B243 Q37409589-86C6CD60-28A5-432D-8CAA-99D760E897E9 Q37642452-6921B7C8-801D-424A-A4B3-4B2BC76F36FB Q38056059-393392C5-7D3B-49A2-959E-80A399237F37 Q38071135-67BA9092-5B2F-4257-9EB9-583C57739BE7 Q38173012-D4F8C416-6427-49B7-88E6-15C8831F8DEB Q38335806-929D90AD-5B76-4EE7-A19B-000E0A687731

P2860

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

http://www.wikidata.org/entity/Q28191637

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@ast

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@en

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@nl

type

label

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@ast

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@en

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@nl

prefLabel

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@ast

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@en

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@nl

P1433

Q28191637-E6CE4F31-E069-4588-AE28-061B33A31CF7

P1476

Q28191637-1CF24E2C-4F0B-45DC-A345-DB9B9A2368FA

P2093

Q28191637-0FFCE154-1DB8-4049-B1BD-1BF089327EDB

Q28191637-395FC074-A7BC-4761-8B3B-9AFE2C76CB19

Q28191637-6A7CDAD3-69FE-4B76-8B0D-97EC138A3AFE

Q28191637-6C6B8793-505E-4971-AB4E-843EA26E3AC9

Q28191637-6D2D87FA-1DF4-4635-B190-144BE65BDE3B

Q28191637-70E1CD43-EB44-42DD-A256-802011D7EC3F

P2888

Q28191637-D254464D-5816-4A44-B133-CD9FD80DF28F

P304

Q28191637-84C67E83-72CE-4B8C-B03C-14445722CD5F

P31

Q28191637-5DAE9924-F052-4B02-97EE-60F8FC543FDD

P356

Q28191637-64C0A733-EC56-421F-AFBD-AF12C449E56F

P407

Q28191637-B057D8A4-BC2F-477E-99A4-7AC5DBB0EBB3

P433

Q28191637-804E87F8-0571-4A4A-AE6F-2A6BB1277F0E

P478

Q28191637-6E8029D8-43B8-48AB-BAC1-37264C73226C

P577

Q28191637-B4E23F1F-3AD6-4FB5-974D-FA2F968264FD

P5875

Q28191637-8C39911B-6023-40DF-931C-EF8436B8F715

P6179

Q28191637-55BA891E-DDD7-4E2E-BFED-B998138A83BD

P698

Q28191637-AEACB107-8D12-4ABD-BA8C-161551D53301

P921

Q28191637-265aee19-c1bd-4e6b-8790-fc692077f604

P356

P1433

Neuropsychopharmacology

P1476

Selective antagonism at dopami ...... e to nicotine-seeking behavior

@en

P2093

Christian A Heidbreder

http://www.w3.org/2001/XMLSchema#string

Enzo Valerio

http://www.w3.org/2001/XMLSchema#string

Jim J Hagan

http://www.w3.org/2001/XMLSchema#string

Maria Pilla

http://www.w3.org/2001/XMLSchema#string

Michela Andreoli

http://www.w3.org/2001/XMLSchema#string

Michela Tessari

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1272-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300183

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10799540

http://www.w3.org/2001/XMLSchema#string

P6179

1007468393

http://www.w3.org/2001/XMLSchema#string

P698

12700694

http://www.w3.org/2001/XMLSchema#string

P921